EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
Post-LOEefavirenz, lamivudine and tenofovir disoproxil fumarate
ANDAORALTABLET
Approved
May 2020
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE (efavirenz, lamivudine and tenofovir disoproxil fumarate) by Viatris (2) is non-nucleoside reverse transcriptase inhibitors [moa]. First approved in 2020.
Drug data last refreshed 18h ago
Mechanism of Action
Non-Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Viatris (2)
China - Shanghai
Worked on EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.